Cargando…
Will introduction of ARNI reduce the need of device therapy in heart failure with reduced ejection fraction?
Autores principales: | Kaur, Navjyot, Pruthvi, CR, Rohit, Manojkumar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966569/ https://www.ncbi.nlm.nih.gov/pubmed/33725186 http://dx.doi.org/10.1186/s43044-021-00152-x |
Ejemplares similares
-
Combined effects of ARNI and SGLT2 inhibitors in diabetic patients with heart failure with reduced ejection fraction
por: Kim, Hyue Mee, et al.
Publicado: (2021) -
SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta‐analysis
por: Yan, Yuling, et al.
Publicado: (2021) -
Real-world comparative effectiveness of ARNI versus ACEi/ARB in HF with reduced or mildly reduced ejection fraction
por: Fu, Michael, et al.
Publicado: (2022) -
Sacubitril/valsartan reduces indications for arrhythmic primary prevention in heart failure with reduced ejection fraction: insights from DISCOVER-ARNI, a multicenter Italian register
por: Pastore, Maria Concetta, et al.
Publicado: (2021) -
Empagliflozin improves cardiac function in heart failure with reduced ejection fraction independent of loading conditions
por: Liang, Bo, et al.
Publicado: (2020)